PDAC remains one of the most daunting challenges in oncology, accounting for over 90 percent of pancreatic cancer cases globally, with a dismal five-year survival rate under five percent for metastatic disease. Current treatment modalities offer limited success; surgical resection is viable for only a fraction of patients with localized disease, while systemic chemotherapy and radiation yield modest benefits and are often accompanied by severe side effects. The pressing need for more effective and precise therapeutic strategies has driven the exploration of molecular targets unique to PDAC cells, with CD44v6 emerging as an especially promising candidate due to its selective tumor-associated expression.

The team led by Professor Marika Nestor at Uppsala University embarked on a multifaceted investigation evaluating the therapeutic potential of [177Lu]Lu-AKIR001, a radioligand labeled with lutetium-177 (^177Lu), a beta-emitting radionuclide known for its utility in targeted cancer treatments. Fundamentally, this agent harnesses the specificity of antibody-based targeting to deliver cytotoxic radiation directly to CD44v6-expressing tumor cells, sparing healthy tissue and reducing systemic toxicity. Initial in vitro analyses confirmed the expression of CD44v6 in three of four tested PDAC cell lines, validating the relevance of this molecular target for heterogeneous pancreatic tumors.

Subsequent in vivo experiments employed murine xenograft models bearing human PDAC tumors, offering a critical platform to evaluate the biodistribution, tumor uptake, and therapeutic efficacy of [177Lu]Lu-AKIR001. Remarkably, the radiopharmaceutical exhibited robust and selective tumor accumulation, as evidenced by quantitative biodistribution studies and corroborated by sophisticated SPECT/CT imaging performed 96 hours post-injection. This selective uptake underscores the precision of the treatment modality, which is fundamental to its therapeutic promise.

Therapeutic interventions administered in these preclinical trials varied in dose and combination with conventional chemotherapy agents to explore synergy and optimize efficacy. Notably, a single administration of 12 megabecquerels (MBq) of [177Lu]Lu-AKIR001 alone resulted in complete tumor regression in 40 percent of cases, while a lower dose of 4 MBq combined with paclitaxel chemotherapy achieved remission in 14 percent of the treated population. These findings delineate an activity-dependent response and provide crucial data for designing dosing regimens in future clinical trials.

A pivotal aspect of the study involved detailed toxicity monitoring to assess the safety profile of [177Lu]Lu-AKIR001. Encouragingly, no significant adverse effects were noted in treated animals, indicating a favorable therapeutic window. This outcome holds immense significance, as systemic toxicities limit the applicability of many radiopharmaceutical and chemotherapeutic agents. The minimized off-target effects arise from the targeted nature of the therapy, which concentrates radioactivity within tumor sites harboring CD44v6 expression.

The advent of targeted radiotherapies has revolutionized treatment paradigms for several malignancies, notably prostate cancer and neuroendocrine tumors. The success of [177Lu]Lu-AKIR001 in preclinical PDAC models expands this therapeutic frontier to a cancer type historically refractory to conventional treatment. Professor Nestor emphasizes the urgent need for new modalities in PDAC management and positions CD44v6-targeted radioligand therapy as a viable candidate to transform clinical outcomes for patients devastated by this malignancy.

Moreover, this work integrates seamlessly within a broader clinical research framework where [177Lu]Lu-AKIR001 is already under evaluation for other cancers in ongoing clinical trials. The expansion of patient inclusion criteria in these programs reflects growing confidence in the agent’s utility and safety, and this preclinical evidence in PDAC provides a compelling rationale for initiating human studies specifically targeting this disease.

The molecular specificity and versatility inherent to [177Lu]Lu-AKIR001 enable it to be potentially combined with existing chemotherapy protocols, enhancing therapeutic potency without exacerbating toxicities. This combinatorial approach may harness synergistic mechanisms that disrupt cancer cell survival pathways more effectively than monotherapies, addressing the heterogeneity and adaptive resistance typical of PDAC. The research team has meticulously mapped the sensitivity profiles of various chemotherapeutic agents against PDAC cell lines, informing personalized treatment designs that optimize combination efficacy.

From a mechanistic perspective, [177Lu]Lu-AKIR001 operates by delivering localized beta radiation, inducing double-stranded DNA breaks within targeted tumor cells, thereby triggering apoptosis and inhibiting proliferation. The therapeutic index of such radioimmunotherapy depends critically on receptor expression density, radioligand affinity, and radionuclide characteristics. This study’s comprehensive biodistribution and binding assays underscore the high affinity and specific delivery capacity of the radiopharmaceutical, crucial parameters for clinical translation.

The high-resolution SPECT/CT imaging employed in this study not only corroborates biodistribution data but also offers valuable insights into in vivo tumor targeting dynamics over time. Visualization at 96 hours post-injection reveals pronounced tumor uptake with minimal accumulation in non-target organs, underscoring the precision of the therapeutic mechanism and allowing for non-invasive assessment of treatment response in live subjects.

Taken collectively, the data present a compelling preclinical proof of concept for [177Lu]Lu-AKIR001 as an effective and safe therapeutic agent against CD44v6-positive PDAC, with significant implications for future clinical practice. This research bridges a critical gap in PDAC treatment, offering a tailored approach that exploits unique tumor biology while preserving patient quality of life through reduced systemic toxicity.

As the clinical investigation of targeted radiotherapies continues to expand, the successful application in PDAC models sets the stage for translational efforts geared towards human trials. The promising preclinical results demonstrated by Professor Nestor and colleagues invigorate the field with a novel therapeutic strategy poised to counteract one of the deadliest cancers, reflecting a pivotal milestone in precision oncology.

Subject of Research: Pancreatic ductal adenocarcinoma (PDAC) treatment using targeted radiopharmaceutical therapy.

Article Title: Open Access [177Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies

News Publication Date: May 13, 2026

Web References:
https://jnm.snmjournals.org/content/early/2026/04/22/jnumed.125.271705
http://dx.doi.org/10.2967/jnumed.125.271705

References:
Gustafsson, A., Svedberg, H., Rinne, S. S., Nestor, M., Bertilsson, F., Lindskog, C., Selvaraju, R. K., & Lundgren Mortensen, A. C. (2026). [177Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies. Journal of Nuclear Medicine.

Image Credits: Amanda Gustafsson (Department of Immunology, Genetics and Pathology, Uppsala University; Science for Life Laboratory, Uppsala University); Anja Mortensen (Department of Immunology, Genetics and Pathology, Uppsala University; Science for Life Laboratory, Uppsala University; Department of Molecular Medicine and Surgery, Karolinska Institutet); Ram Kumar Selvaraju (Department of Medicinal Chemistry, Uppsala University)

Keywords: Targeted radiotherapy, pancreatic ductal adenocarcinoma, CD44v6, [177Lu]Lu-AKIR001, radiopharmaceutical therapy, precision oncology, beta-emitting radionuclide, SPECT/CT imaging, xenograft models, chemotherapy combination, tumor targeting, personalized medicine

It is well established that virtually all PDAC cases arise from activating mutations in the KRAS gene. These mutations produce a constitutively active KRAS protein that drives uncontrolled cell proliferation via downstream signaling cascades such as RAF–MEK–ERK. Notably, clinical efforts to directly inhibit mutant KRAS, especially the KRAS^G12C variant, have seen limited success because the G12C mutation is exceptionally rare in PDAC and tumors rapidly develop resistance to these inhibitors. This presents a formidable challenge, as KRAS remains a critical oncogenic driver with limited therapeutic options.

Exploring the broader landscape of KRAS oncogenic activity, recent investigations have shifted attention towards the cyclin D1-CDK4/6-RB1 axis. Oncogenic KRAS promotes transcriptional upregulation of cyclin D1, which forms an active complex with CDK4/6, leading to phosphorylation and inactivation of RB1. The RB1 protein, a pivotal gatekeeper of cell cycle progression, suppresses proliferation by inhibiting E2F family transcription factors. When RB1 is phosphorylated by cyclin D1-CDK4/6, it becomes functionally disabled, releasing E2F to drive the cell cycle forward.

This antagonistic relationship between KRAS and RB1 is not merely a one-way street. RB1, when active, suppresses a critical post-translational modification— isoprenylation—required for KRAS trafficking to the Golgi apparatus and subsequent activation. Thus, activated RB1 restricts KRAS signaling by impeding its activation cycle. This mutual antagonism establishes a dynamic equilibrium, ensuring that activation of one molecule suppresses the other. Interestingly, while KRAS mutations overwhelmingly dominate PDAC tumorigenesis, mutations in RB1 are rare, implying that RB1 remains largely wild-type and functional in these cancers.

Leveraging this insight, researchers hypothesized that pharmacologic activation of RB1 might indirectly suppress oncogenic KRAS signaling, providing a novel, indirect therapeutic avenue. CDK4/6 inhibitors, already clinically approved for certain breast cancers, inhibit the kinase activity necessary for RB1 phosphorylation, thereby sustaining RB1 in its active, hypophosphorylated state. In theory, this would restore RB1’s tumor suppressive function and counter KRAS-driven malignancy.

Initial investigations into CDK4/6 inhibitor monotherapy for PDAC indeed demonstrated efficacy in inducing cellular senescence—a state of permanent cell cycle arrest with a distinct secretory profile. However, this monotherapy failed to trigger sufficient tumor cell death to produce meaningful clinical benefit. Drawing parallels to breast cancer treatment, where CDK4/6 inhibitors are combined with estrogen receptor blockers, attention turned to identifying synergistic combination therapies to augment antitumor effects.

A pivotal breakthrough came with the identification of ERK inhibitors as potent agents that selectively induced death in PDAC cells harboring an activated RB1 state—mimicking the effects of CDK4/6 inhibition. Counterintuitively, despite expectations that ERK activity would diminish downstream of KRAS suppression by CDK4/6 inhibitors, a robust and sustained ERK reactivation was observed. This paradoxical ERK signaling hinted at an adaptive resistance mechanism dampening the effectiveness of CDK4/6 inhibitors.

Further mechanistic studies revealed that the source of this ERK reactivation was upstream activation of the epidermal growth factor receptor (EGFR) pathway. Upon CDK4/6 inhibition and induction of senescence, PDAC cells exhibited a senescence-associated secretory phenotype (SASP), characterized by secretion of a spectrum of autocrine and paracrine factors, notably EGFR ligands. These ligands potently stimulate EGFR and consequently reactivate ERK signaling via a mechanism likely independent of RAS itself. This EGFR-mediated survival signaling cascade also promotes downstream pro-survival pathways, including those governed by BCL2 and NF-kB, collectively conferring resistance to CDK4/6 inhibitor-induced cell death.

This mechanistic insight inspired a strategic combination approach targeting both CDK4/6 and EGFR signaling axes. Leveraging clinically available EGFR inhibitors, researchers combined CDK4/6 inhibitors with either gefitinib, an EGFR tyrosine kinase inhibitor, or cetuximab, an anti-EGFR monoclonal antibody. Remarkably, these combinations demonstrated potent antitumor efficacy in vitro and in vivo, including in human PDAC xenograft models and genetically engineered mice prone to spontaneous pancreatic cancer development.

Beyond synergistic tumor suppression, this combination therapy exposed an intriguing therapeutic concept: senolysis, the selective elimination of senescent cells. PDAC cells initially entered senescence upon CDK4/6 inhibitor exposure; subsequent EGFR blockade selectively triggered cell death within this senescent population. Notably, this senolytic effect required precise sequencing, as pre-treatment with EGFR inhibitors prior to CDK4/6 inhibition failed to produce similar therapeutic benefits. This underscores the critical importance of treatment scheduling in exploiting the vulnerabilities of senescent cancer cells.

A major concern with senolytic strategies is the potential off-target elimination of normal cells entering senescence, which could result in tissue toxicity. Addressing this, researchers employed sophisticated mouse models expressing reporter constructs for p16, a hallmark of senescence, enabling live tracking of senescent cells in vivo. Encouragingly, CDK4/6 inhibitor treatment did not induce detectable senescence in normal tissues, supporting a favorable therapeutic window and strengthening the translational potential of this combinatorial regimen.

While EGFR inhibitors are traditionally reserved for tumors harboring activating EGFR mutations, PDAC generally lacks such alterations. This limitation is circumvented by the use of anti-EGFR monoclonal antibodies—such as cetuximab—which are efficacious regardless of EGFR mutational status. Consequently, combining CDK4/6 inhibitors with anti-EGFR antibodies represents a pragmatic, immediately translatable clinical strategy for PDAC and potentially other tumors dependent on similar signaling crosstalk.

The implications of this research transcend pancreatic cancer. The paradigm of exploiting the mutual antagonism between oncogenic drivers and tumor suppressors, coupled with exploiting therapy-induced senescence and subsequent senolysis, may revolutionize treatment approaches for various recalcitrant cancers. Moreover, the reliance on already approved agents accelerates the pathway to clinical evaluation, opening avenues for rapid implementation in investigator-initiated trials.

In conclusion, this transformative study elucidates a novel therapeutic vulnerability in PDAC grounded in the reciprocal inhibitory dynamics between KRAS and RB1. Through rational combination therapy employing CDK4/6 inhibitors to activate RB1, paired with EGFR pathway blockade to overcome adaptive resistance, an effective and clinically practicable strategy emerges against one of the deadliest malignancies. This milestone exemplifies how dissecting molecular intricacies can yield powerful therapeutic innovations with far-reaching clinical impact.

Subject of Research: Therapeutic strategies targeting KRAS-driven pancreatic ductal adenocarcinoma via the CDK4/6-RB1 axis and EGFR signaling.

Article Title: Deprivation of EGFR signal causes senolysis in PDAC with CDK4/6 inhibition

News Publication Date: 18-Dec-2025

Web References: DOI: 10.1038/s41418-025-01634-0

References: Takahashi C. et al., Nature Genetics 38, 113–128 (2006); Takahashi C. et al., Cancer Cell 15, 255–269 (2009); Zhang Y. et al., Cell Death and Differentiation (2025).

Image Credits: Chiaki TAKAHASHI

Keywords: Pancreatic Cancer, KRAS Mutation, RB1 Tumor Suppressor, CDK4/6 Inhibitors, EGFR Signaling, Cellular Senescence, Senolysis, ERK Reactivation, Therapeutic Resistance, Combination Therapy

PHOENIX, Ariz. — April 30, 2025 — HonorHealth Research Institute’s new downtown Phoenix laboratory has produced its first study, centered on a promising new treatment for pancreatic cancer, one of the most aggressive and difficult to treat of all malignancies.

Study results were presented April 29 in Chicago at the annual meeting of the 58,000-member American Association for Cancer Research (AACR), the world’s largest professional organization of cancer investigators, caregivers and patient advocates.

Study findings indicate that a newly discovered drug, RMC-6236, also known as Daraxonrasib, is a powerful inhibitor of RAS (including KRAS, NRAS and HRAS). These are commonly mutated cancer-causing genes that drive the formation of many types of tumors, including pancreatic cancer.  This study evaluated the effectiveness of RMC-6236 in patient-derived pancreatic tumors harboring KRAS mutations.

New: Center for Translational Science

According to this initial study to emerge from the Research Institute’s new Center for Translational Science laboratory, RMC-6236, when combined with other proven pancreatic cancer drugs, is a promising new agent against RAS, particularly KRASG12X. Existing KRASG12C inhibitors are unable to target other mutations and often have the unintended result of making  patient tumors drug resistant.

“The fibrotic tumor microenvironment in pancreatic cancer exacerbates therapy resistance, and combining RMC-6236 with other therapies could overcome both intrinsic and acquired resistances,” according to Taylor Bargenquast, a clinical research technician and lead author of the study abstract, which she presented at AACR.

“These results demonstrate the efficacy of RMC-6236 when combined with other therapeutic agents in a pancreatic cancer model — a three dimensional model of pancreatic cancer cells derived from patient biopsies,” said Sunil Sharma, M.D., director of the Center for Translational Science and the senior author of the study abstract.

“The combination of RMC-6236 with standard chemotherapy and targeted therapies enhances its antitumor activity, suggesting a promising strategy for improving therapeutic outcomes in pancreatic cancer,” said Erkut Borazanci, M.D., another of the study’s authors, and medical director of the Institute’s Oncology Research Division.

52,000 Americans expected to die

Pancreatic cancer is the third-leading cause of cancer-related death in the U.S., after lung and colorectal cancers, and is expected to contribute this year to the deaths of nearly 52,000 Americans.

Contributing to this study — Evaluating the efficacy of RAS(ON) inhibitor RMC-6236 combined with chemotherapy and other targeted therapies in 3D models involving patients with KRAS-mutated pancreatic cancer — was the Phoenix-based Translational Genomics Research Institute (TGen), part of City of Hope.

The study suggests that human clinical trials are warranted to further evaluate the safety and effectiveness of RMC-6236.

For more about HonorHealth Research Institute clinical trials: call 833-354-6667; or emailclinicaltrials@Honorhealth.com.

# # #

About the HonorHealth Research Institute
HonorHealth Research Institute is an international destination that is at the forefront of providing patients with a better quality of life through its clinical trials and innovative treatment options. Headquartered in Scottsdale, Arizona, the institute’s team of physicians and researchers collaborate with experts from across the nation to offer life-changing therapies, drugs and devices. At HonorHealth Research Institute, patients have access to tomorrow’s health innovations, today. Learn more at: HonorHealth.com/research.
 

Meeting

AACR Annual Meeting 2025